These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 18495822

  • 1. Physical therapy in anti-TNF treated patients with ankylosing spondylitis.
    Dubey SG, Leeder J, Gaffney K.
    Rheumatology (Oxford); 2008 Jul; 47(7):1100-1. PubMed ID: 18495822
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The treatment of ankylosing spondylitis.
    Scalapino KJ, Davis JC.
    Clin Exp Med; 2003 Feb; 2(4):159-65. PubMed ID: 12624705
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues.
    Jois RN, Gaffney K, Keat A.
    Rheumatology (Oxford); 2007 Jun; 46(6):899-901. PubMed ID: 17308313
    [No Abstract] [Full Text] [Related]

  • 8. FDG-PET/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumour necrosis factor treatment.
    Wendling D, Blagosklonov O, Streit G, Lehuédé G, Toussirot E, Cardot JC.
    Ann Rheum Dis; 2005 Nov; 64(11):1663-5. PubMed ID: 16227425
    [No Abstract] [Full Text] [Related]

  • 9. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H.
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract] [Full Text] [Related]

  • 10. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    Sieper J, Rudwaleit M.
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv61-4. PubMed ID: 16239391
    [Abstract] [Full Text] [Related]

  • 11. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers.
    Hermann J, Müller T, Yazdani-Biuki B, Aringer M, Herold M, Ebner W, Ofner P, Graninger W.
    Ann Rheum Dis; 2007 Apr; 66(4):561-2. PubMed ID: 17360786
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
    [Abstract] [Full Text] [Related]

  • 16. Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy.
    Tzelepis GE, Kalliakosta G, Tzioufas AG, Sfikakis PP, Mandros C, Boki KA, Roussos C, Moutsopoulos HM.
    Ann Rheum Dis; 2009 Jun; 68(6):966-71. PubMed ID: 18633126
    [Abstract] [Full Text] [Related]

  • 17. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
    Gaspersic N, Sersa I, Jevtic V, Tomsic M, Praprotnik S.
    Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH, Rudwaleit M, Listing J, Sieper J.
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [Abstract] [Full Text] [Related]

  • 19. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents.
    Montagna GL, Malesci D, Buono R, Valentini G.
    Ann Rheum Dis; 2005 Nov; 64(11):1667. PubMed ID: 16227427
    [No Abstract] [Full Text] [Related]

  • 20. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.
    Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M.
    Rheumatology (Oxford); 2008 Aug; 47(8):1203-7. PubMed ID: 18524805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.